BioWorld

March 26, 2004

View Archived Issues

Haseltine To Retire As HGS Refocuses, Cuts Employees

In an ever-changing industry, sometimes a biotech company must sacrifice a valuable asset - its people - for the good of the company. Take a bow, Dr. William Haseltine. (BioWorld Today) Read More

Gearing For Estorra Launch, Sepracor Ends Xopenex Deal

Read More

NeoGenesis, AstraZeneca Join For Small-Molecule Discovery

Read More

Point Therapeutics Privately Raising $13.5M For PT-100

Read More

Other News To Note

Read More